Search clinical trials for: sintilimab

Total 436 results

Zhejiang Cancer Hospital

Recruiting

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

Esophageal Squamous Cell Carcinoma

China
Fujian Medical University Union Hospital

Not yet recruiting

Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection

Esophageal Squamous Cell Carcinoma Thoracic Stage II | Esophageal Squamous Cell Carcinoma Thoracic Stage III | Esophageal Squamous Cell Carcinoma Thoracic Stage IV

China
Fudan University

Recruiting

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer (G/GEJ cancer)

Gastric Cancer/Adenocarcinoma of Esophagogastric Junction

China
Fudan University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
The First Hospital of Jilin University

Recruiting

Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma (MB07133)

Efficacy | Safety Issues | MTD

China
Qingdao Central Hospital

Recruiting

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

Metastatic Esophageal Squamous Cell Carcinoma

China
Tang-Du Hospital

Recruiting

Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer

Gastric Cancer

China
Sichuan University
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Advanced Squamous Cell Lung Cancer

Advanced Lung Squamous Cell Carcinoma

China
Fudan University

Recruiting

Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence (IMPROVE)

Colorectal Cancer | Liver Metastases | Radiotherapy | Immunotherapy

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail

Locally Advanced Rectal Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma

Gastric Neuroendocrine Carcinoma

China
Second Affiliated Hospital of Nanchang University

Not yet recruiting

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

Gastric Cancer
Xiaofeng Chen

Recruiting

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Sun Yat-sen University

Recruiting

Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria) (BEST)

Hepatocellular Carcinoma

China
Tongji Hospital

Not yet recruiting

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Hepatocellular Carcinoma

China
Tongji Hospital

Not yet recruiting

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

Hepatocellular Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma (ESCC) | PD-1 Inhibitors

China
Fujian Cancer Hospital

Not yet recruiting

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Advanced Solid Tumor
Sun Yat-sen University

Recruiting

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Sintilimab | Lenvatinib

China
Huashan Hospital

Recruiting

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer

Gastric Cancer

China
Shandong Cancer Hospital and Institute

Recruiting

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Pancreas Cancer

China
Zhejiang Cancer Hospital

Recruiting

Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites

Gastric Cancer | Peritoneal Metastases | Ascites, Malignant

China
Sichuan University

Not yet recruiting

Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

Combined Hepatocellular Cholangiocarcinoma
Sun Yat-sen University

Recruiting

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
Xin-Hua Xu

Recruiting

The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.

Hepatocellular Carcinoma

China
Sun Yat-sen University
Hainan General Hospital

Recruiting

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Neuroblastoma

China
The First Hospital of Jilin University

Not yet recruiting

Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study

Locally Advanced Rectal Cancer | Anti-PD-1 | Total Neoadjuvant Treatment

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Hepatocellular Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...
First People's Hospital of Foshan; Affiliated Cancer Hospital & Institute of... and other collaborators

Recruiting

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Fudan University

Recruiting

Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer

Gastric Cancer | Chemotherapy Effect | Immune Checkpoint Inhibitor

China
Second Xiangya Hospital of Central South University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer (BRIO)

Non Small Cell Lung Cancer | Propranolol
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
jianming xu
NeoCura

Recruiting

A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors

Solid Tumor

China
Xiangya Hospital of Central South University

Not yet recruiting

Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab

Gastric Cancer
Sun Yat-sen University

Recruiting

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital of Jinan University; Shenzhen University General...

Recruiting

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Carcinoma | Digestive System Neoplasms | Intrahepatic Cholangiocarcinoma | First-line Treatment | PD-1 Inhibitor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

MSI-H

China
Tianjin Medical University Cancer Institute and...

Recruiting

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Non-squamous Non-small-cell Lung Cancer

China
Shanghai Jiao Tong University School of Medicine
CSPC Ouyi Pharmaceutical Co., Ltd.; Innovent Biologics, Inc.

Not yet recruiting

Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer (NeoSTEP)

Triple-negative Breast Cancer
Fudan University

Recruiting

The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma (IRIS)

High-Risk Localized Soft Tissue Sarcoma

China
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)

Advanced Intrahepatic Cholangiocarcinoma

China
RenJi Hospital

Not yet recruiting

Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab

Third-line Treatment | Dvanced Duodenal Adenocarcinoma | Furquinelone Combined With Sintilimab
RemeGen Co., Ltd.

Recruiting

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Advanced Solid Tumours

China
Jiangsu Simcere Biologics Co., Ltd

Recruiting

A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors

Advanced Solid Tumor | Cutaneous T Cell Lymphoma

China
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08） (CASTLE-08)

Advanced Biliary Tract Cancer

China
Fudan University

Recruiting

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma (RAPID)

High-Risk Localized Soft Tissue Sarcoma

China
Sun Yat-sen University

Recruiting

Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Metastatic Microsatellite-stable Colorectal Cancer

China

3

Subscribe